Marshall Wace, LLP Savara Inc Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Savara Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 58,593 shares of SVRA stock, worth $259,566. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58,593Holding current value
$259,566% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding SVRA
# of Institutions
122Shares Held
121MCall Options Held
123KPut Options Held
14.7K-
Nea Management Company, LLC Timonium, MD24.5MShares$108 Million8.55% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$64.5 Million10.96% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA10MShares$44.3 Million5.24% of portfolio
-
Jennison Associates LLC8.84MShares$39.2 Million0.03% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.29MShares$36.7 Million0.08% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $505M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.